» Articles » PMID: 27895749

A Single-center Retrospective Study of Pediatric Hepatoblastoma

Overview
Journal Oncol Lett
Specialty Oncology
Date 2016 Nov 30
PMID 27895749
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatoblastoma is a malignant liver tumor generally diagnosed in infants and children <3 years old. The current retrospective study aimed to investigate the associations of tumor stage, pathological type, metastasis and chemotherapy with clinical outcomes. In the current study, a total of 102 patients with hepatoblastoma were enrolled between September 2006 and June 2014. Clinical records and follow-up information for each of patient were obtained to conduct a Kaplan-Meier survival analysis and log-rank test. The median age of the subjects was 1.5 years, and 98 patients had stage III or IV hepatoblastoma. Complete or partial remittance occurred in 72 subjects, and 91 underwent surgical operation. The survival rate differed significantly among patients with different tumor stages (P=0.015, χ=8.359). The mortality rate of stage IV subjects with intrahepatic metastasis was significantly higher than that of those without (P=0.004). Among the 45 subjects with relapsed hepatoblastoma, the mortality rate was higher in the subjects that abandoned chemotherapy than in patients who continued regular chemotherapy. In total, 27 of 45 subjects with relapsed hepatoblastoma succumbed to the disease; 20 of them abandoned chemotherapy treatment; and the remaining 7 patients underwent regular chemotherapy and succumbed to the disease by the end of follow-up. The present study indicates that the increased mortality rate was associated with postoperative residual-induced intrahepatic metastasis and relapsed hepatoblastoma; and that regular chemotherapy is necessary for patient to achieve complete or partial remission following surgical operation.

Citing Articles

Incidence trends and predictive model of hepatic malignant tumors in children: a population-based study.

Xing H, Yang C, Tan B, Zhang M Am J Transl Res. 2022; 14(10):7268-7289.

PMID: 36398244 PMC: 9641436.


Bone metastases in hepatoblastoma, an unusual presentation. Case report and review of the literature.

Barragan V, Escudero M, Jimenez I, Correa C, Luengas J Radiol Case Rep. 2022; 17(11):4272-4275.

PMID: 36124317 PMC: 9482079. DOI: 10.1016/j.radcr.2022.08.025.


Treatment outcomes for hepatoblastoma children with pulmonary metastasis and extrapulmonary involvement: experience of 36 cases at a single institution.

Hu H, Zhang W, Wang Y, Zhang Y, Yi Y, Li F Transl Cancer Res. 2022; 9(10):6402-6411.

PMID: 35117248 PMC: 8798061. DOI: 10.21037/tcr-20-1876.


Clinical Characteristics and Prognosis Analysis of Infantile Hepatoblastoma-A 15-Year Retrospective Single-Center Study.

Zhi T, Zhang W, Zhang Y, Hu H, Huang D Cancer Manag Res. 2021; 13:3201-3208.

PMID: 33883936 PMC: 8053710. DOI: 10.2147/CMAR.S302078.


A single-center retrospective analysis of childhood hepatoblastoma in China.

Yu W, Liu X, Li J, Xi Z, Jin J, Huang H Gland Surg. 2020; 9(5):1502-1512.

PMID: 33224825 PMC: 7667112. DOI: 10.21037/gs-20-710.

References
1.
Otte J, Pritchard J, Aronson D, Brown J, Czauderna P, Maibach R . Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer. 2004; 42(1):74-83. DOI: 10.1002/pbc.10376. View

2.
Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B . Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009; 361(17):1662-70. DOI: 10.1056/NEJMoa0810613. View

3.
Trobaugh-Lotrario A, Katzenstein H . Chemotherapeutic approaches for newly diagnosed hepatoblastoma: past, present, and future strategies. Pediatr Blood Cancer. 2012; 59(5):809-12. DOI: 10.1002/pbc.24219. View

4.
Karski E, Dvorak C, Leung W, Miller W, Shaw P, Qayed M . Treatment of hepatoblastoma with high-dose chemotherapy and stem cell rescue: the pediatric blood and marrow transplant consortium experience and review of the literature. J Pediatr Hematol Oncol. 2014; 36(5):362-8. DOI: 10.1097/MPH.0000000000000130. View

5.
Eicher C, Dewerth A, Ellerkamp V, Fuchs J, Schott S, Armeanu-Ebinger S . Effect of duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) on hepatoblastoma cell lines. Pediatr Surg Int. 2012; 29(2):121-7. DOI: 10.1007/s00383-012-3192-5. View